The aim of this study was to determine the role of the tumor necrosis factor like weak inducer of apoptosis (TWEAK) as a serum biomarker of neuropsychiatric involvement in systemic lupus erythematosus (NPSLE). Levels of TWEAK levels were measured in sera of 92 patients with systemic lupus erythematosus (SLE), including 28 patients with neuropsychiatric lupus, and in 59 healthy controls using ELISA. All SLE patients underwent rheumatological, neurological and psychiatric assessment. We found no significant differences in TWEAK levels, between SLE patients and the healthy controls (p=0.2411). Similarly, no difference was observed between subgroup of NPSLE and healthy controls (p=0.7658). The mean SLE disease activity (SLEDAI) was 13.25. No correlations between TWEAK levels with disease activity (SLEDAI, r=0.2113, p=0.2805) or the most common NPSLE manifestations such as headache (r=0.2079), seizures (r=0.1101), cerebrovascular disease (r= 0.2347), cognitive dysfunction (r=0.1597) and anxiety (r=0.1397) were observed. Our data do not support the use of serum TWEAK as a discriminating biomarker for NPSLE. The role of the TWEAK in NPSLE remains to be investigated.

Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–608. doi: 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F. PubMed DOI

ARINUMA Y, YANAGIDA T, HIROHATA S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2008;58:1130–1135. doi: 10.1002/art.23399. PubMed DOI

BELMONT HM, ABRAMSON SB, LIE JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. Arthritis Rheum. 1996;39:9–22. doi: 10.1002/art.1780390103. PubMed DOI

BERTIN D, STEPHAN D, KHRESTCHATISKY M, DESPLAT-JEGO S. Is TWEAK a biomarker for autoimmune/chronic inflammatory diseases? Front Immunol. 2013;4:489. doi: 10.3389/fimmu.2013.00489. PubMed DOI PMC

BORTOLUZZI A, SCIRE CA, BOMBARDIERI S, CANIATTI L, CONTI F, De VITA S, DORIA A, FERRACCIOLI G, GREMESE E, MANSUTTI E, MATHIEU A, MOSCA M, PADOVAN M, PIGA M, TINCANI A, TOLA MR, TOMIETTO P, VALESINI G, ZEN M, GOVONI M. Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology (Oxford) 2015;54:891–898. doi: 10.1093/rheumatology/keu384. PubMed DOI

BRIANI C, LUCCHETTA M, GHIRARDELLO A, TOFFANIN E, ZAMPIERI S, RUGGERO S, SCARLATO M, QUATTRINI A, BASSI N, ERMANI N, BATTISTIN L, DORIA A. Neurolupus is associated with anti-ribosomal P protein antibodies: an inception cohort study. J Autoimmun. 2009;32:79–84. doi: 10.1016/j.jaut.2008.12.002. PubMed DOI

DESDPLAT-JEGO S, FEUILLET L, CREIDY R, MALIKOVA I, RANCE R, KHRESTCHATISKY M, HAHMK, BURKLY LC, PELLETIER J, BOUCRAUT J. TWEAK is expressed at the cell surface of monocytes during multiple sclerosis. J Leukoc Biol. 2009;85:132–135. doi: 10.1189/jlb.0608347. PubMed DOI

EL-SHEHABY A, DARWEESH H, EL-KHATIB M, MOMTAZ M, MARZOUK S, EL-SHAARAWY N, EMAD Y. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol. 2011;31:848–856. doi: 10.1007/s10875-011-9555-1. PubMed DOI

EL-GENDI SS, EL-SHERIF WT. Anti-C1q antibodies, sCD40L, TWEAK and CD4/CD8 ratio in systemic lupus erythematosus and their relations to disease activity and renal involvement. Egypt J Immunol. 2009;16:135–148. PubMed

FONT J, CERVERA R. 1982 revised criteria for classification of systemic lupus erythematosus--ten years later. Lupus. 1993;2:339–341. doi: 10.1177/096120339300200512. PubMed DOI

FRAGOSO-LOYO H, ATISHA-FREGOSO Y, NUNEZ-ALVAREZ CA, LLORENTE L. Utility of TWEAK to assess neuropsychiatric disease activity in systemic lupus erhytematosus. Lupus. 2016;25:364–369. doi: 10.1177/0961203315610206. PubMed DOI

FRIERI M. Mechanisms of disease for the clinician: systemic lupus erythematosus. Ann Allergy Asthma Immunol. 2013;110:228–232. doi: 10.1016/j.anai.2012.12.010. PubMed DOI

GAO HX, CAMPBELL SR, BURKLY LC, JAKUBOWSKI A, JARCHUM I, BANAS B, SALEEM MA, MATHIESON PW, BERMAN JW, MICHALESON JS, PUTTERMAN C. TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokine. 2009;46:24–35. doi: 10.1016/j.cyto.2008.12.001. PubMed DOI

HANLY JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol. 2014;10:338–347. doi: 10.1038/nrrheum.2014.15. PubMed DOI

HANLY JG, Mc CURDY G, FOUGERE L, DOUGLASJA, THOMPSON K. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol. 2004;31:2156–2162. PubMed

HANLY JG, UROWITZ MB, SU L, BAE SC, GORDON C, WALLACE DJ, CLARKE A, BERTNATSKY S, ISENBERD D, RAHMAN A, ALACRON GS, GLADMAN DD, FORTIN PR, SANCHZ-GUERRERO J, ROMERO-DIAR J, MERRIL JT, GINZLER E, BRUCE IN, STEINSSON K, KHAMASHTA M, PETRI M, MANZI S, DOOLEY MA, RAMSEY-GOLDMAN R, van VOLLENHOVEN R, NIVED O, STURFELT G, ARANOW C, KALUNIAN K, RAMON-CASALS M, ZOMA A, DOUGLAS J, THOMSON K, FAREWELL V. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2010;69:529–535. doi: 10.1002/art.22305. PubMed DOI PMC

ISSHI K, HIROHATA S. Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum. 1998;41:1819–1827. doi: 10.1002/1529-0131(199810)41:10<1819::aid-art14>3.0.co,2-y. PubMed DOI

JEONG HW, HER M, BAE JS, KIM SK, LEE SW, KIM HK, KIM D, PARK N, CHUNG WT, LEE SY, CHOE JY, KIM IJ. Brain MRI in neuropsychiatric lupus: associations with the 1999 ACR case definitions. Rheumatol Int. 2015;35:861–869. doi: 10.1007/s00296-014-3150-8. PubMed DOI

JOSEPH FG, SCOLDING NJ. Neurolupus. Pract Neurol. 2010;10:4–15. PubMed

KANG EH, SHEN GQ, MORRIS R, METZGER A, LEE EY, LEE YJ, LEE EB, SONG YW. Flow cytometric assessment of anti-neuronal antibodies in central nervous system involvement of systemic lupus erythematosus and other autoimmune diseases. Lupus. 2008;17:21–25. doi: 10.1177/0961203307085256. PubMed DOI

KASAMA T, MAEOKA A, OGURO N. Clinical features of neuropsychiatric syndromes in systemic lupus erythematosus and other connective tissue diseases. Clin Med Insights Arthritis Musculoskelet Disord. 2016;9:1–8. doi: 10.4137/cmamd.s37477. PubMed DOI PMC

KOZORA E, HANLY JG, LAPTEVA L, FILLEY CM. Cognitive dysfunction in systemic lupus erythematosus: past, present, and future. Arthritis Rheum. 2008;58:3286–3298. doi: 10.1002/art.23991. PubMed DOI

LIU ZC, ZHOU QL, LI XZ, YANG JH, AO X, VEERARAGOO P, ZUO XX. Elevation of human tumor necrosis factor-like weak inducer of apoptosis in peripheral blood mononuclear cells is correlated with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Cytokine. 2011;53:295–300. doi: 10.1016/j.cyto.2010.11.012. PubMed DOI

MAGRO-CHECA C, ZIRKZEE EJ, HUIZINGA TW, STEUP-BEEKMAN GM. Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives. Drugs. 2016;76:459–483. doi: 10.1007/s40265-015-0534-3. PubMed DOI PMC

MENNON S, JAMESON-SHORTALL E, NEWMAN SP, HALL-CRAGGS MR, CHINN R, ISENBERG DA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum. 1999;42:735–741. doi: 10.1002/1529-0131(199904)42:4<735::aid-anr17>3.0.co,2-l. PubMed DOI

OGAWA E, NAGAI T, SAKUMA Y, ARINUMA Y, HIROHATA S. Association of antibodies to the NR1 subunit of N-methyl-D-aspartate receptors with neuropsychiatric systemic lupus erythematosus. Mod Rheumatol. 2016;26:377–383. doi: 10.3109/14397595.2015.1083163. PubMed DOI

PAMFIL C, FANOURIAKIS A, DAMIAN L, RINZIS M, SIDIROPOULOS P, TSIVGOULIS G, REDNIC C, BERTSIAS G, BOUMPAS DT. EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres. Rheumatology (Oxford) 2015;54:1270–1278. doi: 10.1093/rheumatology/keu482. PubMed DOI

PERRICONE C, PENDOLINO M, OLIVIERI M, CONTI F, VALESINI G, AALESSANDRI Neuropsychiatric manifestations associated with anti-endothelial cell antibodies in systemic lupus erythematosus. Isr Med Assoc J. 2015;17:171–178. PubMed

POLAVARAPU R, GONGORA MC, WINKLES JA, YEPES M. Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor-kappa B pathway activation. J Neurosci. 2005;25:10094–10100. doi: 10.1523/jneurosci.3382-05.2005. PubMed DOI PMC

POPESCU A, KAO AH. Neuropsychiatric systemic lupus erythematosus. Curr Neuropharmacol. 2011;9:449–457. doi: 10.2174/157015911796557984. PubMed DOI PMC

RUIZ-ORTEGA M, ORTIZ A, RAMOS AM. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and kidney disease. Curr Opin Nephrol Hypertens. 2014;23:93–100. doi: 10.1097/01.mnh.0000437331.23794.81. PubMed DOI

SARBU N, ALOBEIDI F, TOLEDANO P, ESPINOSA G, GILES I, RAHMAN A, YOUSRY T, CAPURRO S, JAGER R, CERVERA R, BARGALLO N. Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. Autoimmun Rev. 2015;14:153–159. doi: 10.1016/j.autrev.2014.11.001. PubMed DOI

SCHWARTZ N, RUBINSTEIN T, BURKLY LC, COLLINS CE, BLANCO I, SU L, HOJAILI B, MACKAY M, ARANOW C, STOHL W, ROVIN BH, MICHAELSON JS, PUTTERMAN C. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther. 2009;11:R143. doi: 10.1186/ar2816. PubMed DOI PMC

SCHWARTZ N, SU L, BURKLY LC, MACKAY M, ARANOW C, KOLLAROS M, MICHAELSON JS, ROVIN BHPUTTERMAN C. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun. 2006;27:242–250. doi: 10.1016/j.jaut.2006.12.003. PubMed DOI

SIBBIT WL, JR, BRANDT JR, JOHNSON CR, MALDONADO ME, PATEL SR, FORD CC, BANKHURST AD, BROOKS WM. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol. 2002;29:1536–1542. PubMed

WANG C, CHEN LL, PAN HF, LENG RX, QIN WT, YE DQ. Expression of human tumor necrosis factor-like weak inducer of apoptosis in patients with systemic lupus erythematosus. Clin Rheumatol. 2012;31:335–339. doi: 10.1007/s10067-011-1865-4. PubMed DOI

WEN J, DOERNER J, WEIDENHEIM K, XIA Y, STOCK A, MICHAELSON JS, BURKLY LC, GULINELLO M, PUTTERMAN C. TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice. J Autoimmun. 2015;60:40–50. doi: 10.1016/j.jaut.2015.03.005. PubMed DOI PMC

WEN J, XIA Y, STOCK A, MICHAELSON JS, BURKLY LC, GULINELLO M, PUTTERMAN C. Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway. J Autoimmun. 2013;43:44–54. doi: 10.1016/j.jaut.2013.03.002. PubMed DOI PMC

WILSON HA, WINFIELD JB, LAHITA RG, KOFFLER D. Association of IgG anti-brain antibodies with central nervous system dysfunction in systemic lupus erythematosus. Arthritis Rheum. 1979;22:458–462. doi: 10.1002/art.1780220504. PubMed DOI

WINKLES JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov. 2008;7:411–425. doi: 10.1038/nrd2488. PubMed DOI PMC

XU WD, ZHAO Y, LIU Y. Role of the TWEAK/Fn14 pathway in autoimmune diseases. Immunol Res. 2016;64:44–50. doi: 10.1007/s12026-015-8761-y. PubMed DOI

XUEJING Z, JIAZHEN T, JUN L, XIANGQING X, SHUGUANG Y, FUYOU L. Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. J Biomed Biotechnol. 2012:359647. doi: 10.1155/2012/359647. PubMed DOI PMC

YAZDANY J. Health-related quality of life measurement in adult systemic lupus erythematosus: Lupus quality of life (LupusQoL), Systemic lupus erythematosus-specific quality of life questionnaire (SLEQOL), and Systemic lupus erythematosus quality of life Questionnaire (L-QoL) Arthritis Care Res (Hoboken) 2011;63(Suppl 11):S413–419. doi: 10.1002/acr.20636. PubMed DOI PMC

YOSHIO T, OKAMOTO H, KURASAWA K, DEI Y, HIROHATA S, MINOTA S. IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus. Lupus. 2016;25:997–1003. doi: 10.1177/0961203316629556. PubMed DOI

ZIRKZEE EJ, STEUP-BEEKMAN GM, van der MAST RC, BOLLEM EL, van der WEE NL, BAPTIST E, SLEE TM, HUISMAN MV, MIDDELKOOP HA, LUYENDIJK J, van BUCHEM MA, HUIZINGA TW. Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus, multidisciplinary approach to diagnosis and therapy. J Rheumatol. 2012;39:2118–2126. doi: 10.3899/jrheum.120545. PubMed DOI

Elevated serum neurofilament light chain levels in patients with neuropsychiatric systemic lupus erythematosus: a cross-sectional study